COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02100891
Recruitment Status : Active, not recruiting
First Posted : April 1, 2014
Last Update Posted : August 18, 2020
Information provided by (Responsible Party):
Monica Thakar, Medical College of Wisconsin

Brief Summary:

The investigators hypothesize that this Phase 2 cellular and adoptive immunotherapy study using human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) followed by an early, post-transplant infusion of donor natural killer (NK) cells on Day +7 will not only be well-tolerated in this heavily-treated population (safety), but will also provide a mechanism to treat high-risk solid tumors, leading to improved disease control rate (efficacy). Disease control rate is defined as the combination of complete (CR) and partial (PR) response and stable disease (SD). The investigators further propose that this infusion of donor NK cells will influence the development of particular NK and T cell subtypes which will provide immediate/long-term tumor surveillance, infectious monitoring, and durable engraftment.

Patients with high-risk solid tumors (Ewings Sarcoma, Neuroblastoma and Rhabdomyosarcoma) who have either measurable or unmeasurable disease and have met eligibility will be enrolled on this trial for a goal enrollment of 20 patients over 4 years.

Condition or disease Intervention/treatment Phase
Ewing Sarcoma Neuroblastoma Rhabdomyosarcoma Osteosarcoma CNS Tumors Procedure: Allogeneic HCT Drug: Donor NK Cell Infusion Phase 2

Detailed Description:

Patients will receive a reduced-intensity conditioning regimen for 6 days that consists of Fludarabine 150 mg/m2, Cyclophosphamide 29 mg/kg, and 3 Gy total body irradiation (TBI), followed by HLA-haploidentical marrow from a family member on Day 0. On Days +3 and +4, Cyclophosphamide 50 mg/kg will be infused for selective in vivo T cell depletion. Additional post-grafting immune suppression will consist of mycophenolate mofetil and either tacrolimus or sirolimus.

Non-mobilized peripheral blood mononuclear cells will be collected from donors on Day +6, from which NK cells will be selected and infused into patients on Day +7.

Patients will be monitored for any transplant-related complications and will undergo disease monitoring every three months for the first two years post-transplant. Research studies will be conducted to follow the patient's immune status and quality of life post-transplant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR Trial
Study Start Date : March 2014
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Allogeneic HCT + Donor NK Cell Infusion
Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
Procedure: Allogeneic HCT
Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
Other Names:
  • Haplo transplant
  • Reduced-intensity conditioning
  • Bone marrow transplant

Drug: Donor NK Cell Infusion
Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
Other Names:
  • Natural Killer Cells
  • Adoptive immunotherapy
  • Donor Lymphocyte Infusion
  • IND 13794

Primary Outcome Measures :
  1. Disease-control rate [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 1 year ]

Other Outcome Measures:
  1. Non-relapse mortality [ Time Frame: Day +100 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. No age restrictions
  2. Only subjects who are not appropriate candidates for autologous or HLA-matched sibling hematopoietic cell transplants (HCT) may be enrolled.
  3. Diseases eligible

    1. High Risk Neuroblastoma (NB): Must have progressed on or recurred after standard frontline therapy including autologous HCT, or be ineligible for autologous HCT.
    2. Ewing Sarcoma Family of Tumors (EWS) [includes both bone and soft tissue Ewing and Peripheral Primitive Neuroectodermal Tumors (PNET)]. Must have progressed on or recurred after standard frontline therapy which includes doxorubicin and ifosfamide.
    3. High-Risk Rhabdomyosarcoma (RMS) or Intermediate Risk Alveolar RMS recurring as more than loco-regional tumor: Must have progressed on or recurred after standard frontline therapy which includes chemotherapy with vincristine, actinomycin, and cyclophosphamide AND either surgery or radiotherapy.
    4. Osteosarcoma: Must have progressed or recurred after standard frontline therapy. If first relapse, must have recurred with a) ≥ 4 lung nodules; b) bilateral lung involvement; or c) relapse outside the lungs.
    5. CNS tumors: High risk malignant brain tumors that are recurrent or refractory to standard frontline therapy are eligible. Diagnoses include: Medulloblastoma, primitive neuro-ectodermal tumor (PNET), ependymoma, high grade (grade 3 or 4) glioma/astrocytoma, germ-cell tumor, or atypical teratoid-rhabdoid tumor (ATRT)

Exclusion Criteria

  1. Rapidly-progressing disease prior to HCT, defined as clinical or radiographic evidence of disease progression ≤ 3 weeks prior to protocol registration despite previous achievement of stable or no disease (Appendix C & D) (Note: after disease eligibility has been determined, additional imaging studies are not necessary during the three weeks before the start of conditioning unless there are clinical concerns).
  2. Patients who have reached radiation threshold limits and are excluded from receiving 3 Gy TBI.
  3. Diffuse intrinsic pontine gliomas (DIPG) are excluded.
  4. Performance status: Karnofsky or Lansky <60% Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  5. Patients, who in the opinion of the investigator, may not be able to comply with the treatment plan or safety monitoring requirements of the study Page 16 of 86 Children's Hospital of Wisconsin Medical College of Wisconsin PI: Monica S. Thakar, MD
  6. Significant organ dysfunction that would prevent compliance with conditioning, GVHD prophylaxis, or would severely limit the probability of survival, defined as:

    1. Cardiac: For patients not taking inotropic medications and who do not have cardiac failure requiring therapy: Symptomatic coronary artery disease or ejection fraction <35% or, if unable to obtain ejection fraction, shortening fraction of <26%. If shortening fraction is <26% a cardiology consult is required with the PI having final approval of eligibility. For patients taking inotropic medications: Patients displaying corrected cardiac function will be eligible, i.e., patients who take inotropic medications to maintain EF ≥ 35% and SF≥ 26% cardiac function eligibility.
    2. Pulmonary: DLCO <40% TLC <40%, FEV1 <40% and/or receiving supplementary continuous oxygen
    3. Liver: Patient with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension. The patient will be excluded if he/she is found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3mg/dL, or symptomatic biliary disease
  7. Patients with serious active infections
  8. HIV seropositive patients
  9. Patients with poorly controlled hypertension despite multiple antihypertensive medications
  10. Fertile females who are unwilling to use contraceptive techniques during and for the twelve months following treatment, as well as females who are pregnant or actively breast feeding
  11. Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment
  12. Life expectancy severely limited by diseases other than malignancy
  13. Patients who have received a prior allogeneic HCT are ineligible

DONOR SELECTION An Unrelated Donor Search is not required for entry on this trial. Lack of HLA-matched related or unrelated donors is not a requirement for entry on this trial.

A. Inclusion Criteria

  1. Related, HLA-haploidentical donors who are identical for one HLA haplotype and mismatched for any number of HLA-A, -B, -C, DRB1 or DQB1 loci of the unshared haplotype.
  2. Marrow will be prioritized as the hematopoietic stem cell source of choice. In cases where adequate stem cells cannot be collected, fresh (preferred) or cryopreserved donor PBSC may be substituted. In the case that PBSC are used, the donor must be 18 years of age or older.
  3. HLA-haploidentical donor selection will be based on standard institutional criteria; otherwise no specific prioritization will be made amongst the suitable available donors.

B. Exclusion Criteria

  1. Children less than 12 years of age (marrow) or less than 18 years of age (PBSC).
  2. Children greater than or equal to 12 years of age who have not provided informed assent in the presence of a parent and an Attending physician who is not a member of the recipient's care team
  3. Children greater than or equal to 12-17.9 years of age who have inadequate peripheral vein access to safely undergo apheresis
  4. Donors unable or unwilling to undergo marrow harvest or PBSC collection for the initial HCT, storage of autologous blood prior to marrow harvest (if applicable), or apheresis one week after marrow harvest
  5. Donors who are not expected to meet the minimum target dose of marrow cells (1 x 108 total nucleated cells/kg recipient weight) for the initial marrow HCT or PBSC transplant (5.0 x 106 CD34/kg recipient weight). The average nucleated cell content of harvested marrow is 22 x 106 nucleated cells/mL or 220 x 108 total nucleated cells/Liter
  6. HIV-positive donors
  7. Donors who are cross-match positive with recipient

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02100891

Layout table for location information
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Monica Thakar
Layout table for investigator information
Principal Investigator: Monica Thakar, MD Medical College of Wisconsin
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Monica Thakar, Associate Professor of Pediatrics Blood and Marrow Transplant Program, Medical College of Wisconsin Identifier: NCT02100891    
Other Study ID Numbers: STIR Trial
First Posted: April 1, 2014    Key Record Dates
Last Update Posted: August 18, 2020
Last Verified: August 2020
Keywords provided by Monica Thakar, Medical College of Wisconsin:
Ewing Sarcoma
CNS tumors
Brain Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Ewing
Central Nervous System Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases